Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenue from product sales	$ 270	$ 170	$ 200
Collaboration revenue	222	10	0
Total revenue	492	180	200
Cost of product sales	426	2,312	7,501
Cost of collaboration revenue	296	0	0
Total cost of revenue	722	2,312	7,501
Gross loss	(230)	(2,132)	(7,301)
Research and development expenses	9,968	8,342	3,638
Selling, general and administrative expenses	11,285	10,087	9,440
Operating loss	(37,407)	(29,954)	(30,503)
Other income (expense):
Warrant revaluation and other finance income (expense)	2,929	3,930	(1,053)
Other income	17	368	0
Interest income	8	6	2
Loss before income taxes	(34,453)	(25,650)	(31,554)
Income tax benefit	0	0	0
Net loss	$ (34,453)	$ (25,650)	$ (31,554)
Per Share Information:
Net loss per share, basic (in dollars per share)	$ (0.82)	$ (0.63)	$ (1.06)
Net loss per share, diluted (in dollars per share)	$ (0.85)	$ (0.70)	$ (1.12)
Weighted average number of common shares outstanding
Weighted average number of common shares outstanding - basic (in shares)	42,178,397	40,789,445	29,830,207
Weighted average number of common shares outstanding - diluted (in shares)	42,351,346	40,969,399	30,196,616
Affiliated Entity
Research and development expenses	$ 15,924	$ 9,393	$ 10,124